Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience

被引:0
|
作者
David Wyndham Lawrence
Robin Carhart-Harris
Roland Griffiths
Christopher Timmermann
机构
[1] University of Toronto,Department of Family & Community Medicine, Faculty of Medicine
[2] Mount Sinai Hospital,Faculty of Kinesiology & Physical Education
[3] Sinai Health System,Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences
[4] University of Toronto,Psychedelics Division, Neuroscape, Department of Neurology
[5] Imperial College London,Departments of Psychiatry and Neuroscience, Center for Psychedelic and Consciousness Research
[6] University of California,undefined
[7] Johns Hopkins University School of Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Understanding the phenomenology and content of the inhaled N, N, dimethyltryptamine (N, N-DMT) experience is critical to facilitate and support ongoing research and therapeutic models targeting mental health conditions and central nervous system pathology. A qualitative analysis was conducted of all N, N-DMT experiences posted to the r/DMT Reddit community over a 10-year period from 2009 to 2018. A total of 3778 experiences from 3305 posts were included in this study. A median dose of N, N-DMT of 40.0 mg [interquartile range (IQR), 27.5 to 50.0] and a median experience duration of 10 min (IQR, 5.0 to 15.0) were identified. The most common somatic effects were somaesthesias (n = 1415, 37.5%) and an auditory ringing (n = 583, 15.4%). Visualizations predominantly consisted of fractals, shapes, patterns (n = 1231, 32.6%) and vivid colours (n = 953, 25.2%). Entity encounters were reported in 45.5% (n = 1719) of the experiences and involved predominantly a feminine phenotype (n = 416, 24.2%); deities (n = 293, 17.0%); aliens (n = 281, 16.3%); creature-based entities (n = 158, 9.2%, including reptilian and insectoid beings); mythological beings (n = 144, 8.4%, including machine elves); and jesters (n = 112, 6.5%). Entity interactions were predominantly positive (n = 600, 34.9% of encounters) involving benevolent, comforting, protecting, or outwardly caring interactions. A companion-type, pedagogical, or guide-type interaction was identified 32.4% of encounters (n = 557). Common typology, architecture, and structural features of the “DMT world” included descriptions of alternate or higher dimensions (n = 952, 25.2%); rooms [n = 582, 15.4%, including the “waiting room” (n = 105, 2.8%)], and a tunnel (n = 390, 10.3%). Features of mystical and ego-dissolution experiences were common. Additional rewarding aspects were identified, including a sense of familiarity and the acceptance/removal of the fear of death. Challenging and difficult responses were less frequent but also documented. Statements of profundity were identified in 232 experiences (6.1%), including pronouncing the experience or an aspect of the experience as the most “beautiful” or feeling the most “beautiful” of their life (n = 47, 1.2%). This study identified common phenomenological themes and content of naturalistic inhaled N, N-DMT experiences. Major thematic domains included (1) physical and somatic experiences; (2) visualizations and imagery; (3) entity encounters including entity phenotype, descriptors, attributes, disposition, and characteristics of the interaction; (4) typology, architectural features, structural characteristics, and scenery of the “DMT world”; (5) alerations in consciousness (including mystical experiences, out-of-body experiences, and ego-dissolution); (6) emotional responses (including positive, rewarding, difficult, and challenging); and (7) statements of profundity.
引用
收藏
相关论文
共 50 条
  • [21] Continuous flow synthesis of N,N-dimethyltryptamine (DMT) analogues with therapeutic potential
    Simoens, Andreas
    Dejaegere, Andreas
    Vandevelde, Marthe
    Stevens, Christian V.
    RSC MEDICINAL CHEMISTRY, 2025, 16 (01): : 367 - 372
  • [22] INDOLE HALLUCINOGENS, N,N-DIMETHYLTRYPTAMINE (DMT) AND 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT), HAVE DIFFERENT EFFECTS FROM MESCALINE ON RAT SHUTTLEBOX AVOIDANCE
    STOFF, DM
    GORELICK, DA
    BOZEWICZ, T
    BRIDGER, WH
    GILLIN, JC
    WYATT, RJ
    NEUROPHARMACOLOGY, 1978, 17 (12) : 1035 - 1040
  • [23] N,N-dimethyltryptamine facts and myths
    Barker, Steven A.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2018, 32 (07) : 820 - 821
  • [24] N,N-DIMETHYLTRYPTAMINE IN NORMAL SUBJECTS
    KAPLAN, J
    STILMAN, RC
    MANDEL, L
    GILLIN, JC
    WYATT, RJ
    PSYCHOSOMATIC MEDICINE, 1974, 36 (05): : 456 - 456
  • [25] Pharmacokinetics of N,N-dimethyltryptamine in Humans
    Meghan Good
    Zelah Joel
    Tiffanie Benway
    Carol Routledge
    Chris Timmermann
    David Erritzoe
    Richard Weaver
    Graham Allen
    Charlotte Hughes
    Helen Topping
    Amy Bowman
    Ellen James
    European Journal of Drug Metabolism and Pharmacokinetics, 2023, 48 : 311 - 327
  • [26] BIOSYNTHESIS AND TURNOVER OF N,N-DIMETHYLTRYPTAMINE AND 5-METHOXY-N,N-DIMETHYLTRYPTAMINE IN PHALARIS-TUBEROSA
    BAXTER, C
    SLAYTOR, M
    PHYTOCHEMISTRY, 1972, 11 (09) : 2767 - &
  • [27] Pharmacokinetics of N,N-dimethyltryptamine in Humans
    Good, Meghan
    Joel, Zelah
    Benway, Tiffanie
    Routledge, Carol
    Timmermann, Chris
    Erritzoe, David
    Weaver, Richard
    Allen, Graham
    Hughes, Charlotte
    Topping, Helen
    Bowman, Amy
    James, Ellen
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2023, 48 (03) : 311 - 327
  • [28] Human psychopharmacology of N,N-dimethyltryptamine
    Strassman, RJ
    BEHAVIOURAL BRAIN RESEARCH, 1996, 73 (1-2) : 121 - 124
  • [29] URINARY-EXCRETION OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE, N,N-DIMETHYLTRYPTAMINE AND THEIR N-OXIDES IN THE RAT
    SITARAM, BR
    LOCKETT, L
    BLACKMAN, GL
    MCLEOD, WR
    BIOCHEMICAL PHARMACOLOGY, 1987, 36 (13) : 2235 - 2237
  • [30] HYDROXYLATION AND N-DEMETHYLATION OF N,N-DIMETHYLTRYPTAMINE
    SZARA, S
    AXELROD, J
    EXPERIENTIA, 1959, 15 (06): : 216 - 217